EDAS Healthcare is a patented decision support software, enabling immediate prediction of an infectious disease, upon the first patient encounter with a physician. Based on the research at Hadassah Medical Center (Jerusalem), EDAS Healthcare provides instant lab-grade AI detection of respiratory infectious diseases and COVID-19 for use in primary care and telemedicine. The company’s solution detects the patient’s specific infecting pathogen using only anonymous patient demographics and without any physical tests or equipment, and even for a-symptomatic COVID-19 patients.
Together with Hadassah Medical Center and Tel Aviv Sourasky Medical Center (Ichilov), I-Medata Center, EDAS Healthcare won a grant for pilot real-time use of its solution for remote diagnosis of COVID-19 in a year-long research project. The company has made great progress this year and is gearing up for commercial pilots with Hospitals and HMOs in Israel and Europe. EDAS Healthcare solution has been successfully clinically validated at the Hadassah Medical Center with over 50,000 patients to date, providing a real-time detection of 10 different viruses and 5 different bacteria.
EDAS Healthcare is currently looking for its seed funding that will allow the company to reach full commercialization within a year time.
In times of the COVID-19 pandemic, healthcare systems struggle to test mass population to contain and monitor the epidemic and allow economies returning to “new normal” life. Most respiratory infectious diseases, including COVID-19, have very similar symptoms thus are not reliably identified due to a lack of diagnosis capacity. An increasing number of infectious agents are not easily and effectively identified without laboratory tests. This puts the critical medical teams in danger, leads to sub-optimal treatment which translates into severe medical and financial consequences. Furthermore, with a highly infective disease such as COVID-19, conventional diagnostics are not fast enough to arrest the spread of the disease. The ability to eliminate infection for the masses from remote is key for an effective pandemic monitoring. EDAS Healthcare instantly detects and eliminates the causative agents of respiratory infectious diseases, without any physical examination or devices! allowing Physician and healthcare agencies to receive accurate results in a seconds and with no capacity limitation, whether patient is infected with a respiratory infectious disease or not, such as flu or COVID-19.
“This could be a game changer for all global healthcare systems in delivering primary care treatment, fighting the COVID-19 pandemic, and for Governments managing economic in the “New normal” situation.” said Guy Livne, EDAS CEO.
EDAS Healthcare also won the EU Horizon 2020 SME phase 1 grant last year.
EDAS Healthcare’s underlying technology is the product of research focused on the transmission of pathogens in the urban and sub-urban spatial resolution scales.
“Understanding the dynamics of how pathogen spread within these areas is critical for the effective prevention and containment of communicable diseases.” said Prof. Nir-Paz, from the Department of Microbiology and Infectious Diseases at Hadassah Medical Center as well as medical advisor to EDAS Healthcare .
Artificial Intelligence, Big Data and Machine Learning is applied to process the historical regional laboratory test results to track and predict the respiratory disease epidemiology. The result is the ability to do mass screening over Tele-Medicine or at Point-Of-Care and diagnosis for pathogens in seconds at a fraction the cost of laboratory tests.
About EDAS Healthcare
EDAS Healthcare is a digital health startup providing instant, lab-grade AI detection of respiratory infectious diseases and COVID-19 for Primary Care & Tele-Medicine. EDAS patented lab-grade AI, detects the specific infecting pathogen for patients, by using anonymous patient demographics only and without any physical tests or equipment, allowing accurate diagnosis for Primary Care & Tele-Medicine. In COVID-19 pandemic era, EDAS system can screen mass populations for infection in seconds, thus may serve as a key to allow economies to return to the ‘new normal’ Founded in 2018, EDAS unique technology was developed and validated at Hadassah Medical Center, Jerusalem led by Prof Ran Nir-Paz, from the Department of Microbiology and Infectious Diseases. EDAS had been granted a US patent for its technology which redefines the way respiratory infectious diseases are diagnosed.
For further information https://www.edashealthcare.com/
Source: EDAS Healthcare
About JLM- BioCity
News on the many life science and healthcare companies in the Jerusalem area can be seen at https://jlm-biocity.org/jlm-biocity-innovations/
JLM-BioCity https://jlm-biocity.org/ is a non-profit organization focused on developing and excelling Jerusalem’s bio-community.
We invite you, researcher, professional, investor and executive to become part of our vision, in building Jerusalem’s Biomed eco-system.
If you want your Company featured in our blogs , news releases, please contact: info at jlm-biocity.org
